@misc{oai:repo.qst.go.jp:00063728,
 author = {Ｕ, Ｗｉｎｎ Ａｕｎｇ and Ｕ Ｗｉｎｎ Ａｕｎｇ},
 month = {Nov},
 note = {In addition to conventional cancer therapies, gene therapy has been expected to cure the malignant diseases and one of the attractive areas of preclinical and clinical research. Application of non-invasive molecular imaging to cancer gene therapy will enable to assess therapeutic process in real-time and to adjust the treatment protocols and techniques timely. Indirect imaging strategy basing on the use of reporter gene technology has been well utilized as an approach to address the issues like monitoring of the location, magnitude and the duration of vector-mediated gene expression, in vivo vector biodistribution, tracking the migration of labeled cells, evaluation of tumor progression or regression and etc. With various strategies, linking of imaging reporter gene and therapeutic gene could be performed for simultaneous expression. Reporter gene imaging for different imaging modalities, such as optical imaging, radionuclide imaging (PET, SPECT) and magnetic resonance imaging (MRI) have been developed, and the techniques and protocols are dynamically progressing. Moreover, the development of customized gene transfer vectors will facilitate to halt or regulate the expression levels of the introduced transgene especially when undesired adverse effects happen, or to sustain a particular expression that can improve the therapeutic efficiency. Considering these, for tumor suppressor protein (p53) gene therapy, development of novel gene transfer vector with regulative gene expression system and feasibility to simultaneously monitor with reporter gene become also important. 
In this presentation, I will discuss about our study using doxycyline-regulated bidirectional TRE-tight novel vector harboring a reporter gene encoding the red fluorescence protein (RFP), and tumor suppressor protein (wild-type p53), by which we demonstrate the inducible and simultaneous and coordinated expression of both protein in vitro and in vivo. Moreover, we also demonstrate that the reduced 18F-FDG uptake in tumor with induced wild-type p53 over expression, and postulate that FDG-PET can be used as a surrogate indicator for monitoring tumor response to p53 gene therapy., 第4回分子イメージング研究センターシンポジウム},
 title = {癌の遺伝子治療における非侵襲的なイメージングの応用},
 year = {2009}
}